Transcatheter implantation of the Ventura interatrial shunt is safe but does not lead to improved clinical outcomes in patients with heart failure (HF) and preserved left ventricular ejection fraction ...

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

Therapies are needed for patients with heart failure with mildly reduced or preserved ejection fraction. New research findings on the nonsteroidal mineralocorticoid receptor antagonist finerenone ...

A low ejection fraction lets a doctor know that the active pumping phase of the heart isn't working. It's usually tied to some, but not all, types of heart failure. Heart failure with a low EF is ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

TX45 is being evaluated in the APEX phase 2 clinical trial (NCT06616974) in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). The trial is ...

Systolic heart failure happens when the heart pumps at 40% or less of its ejection fraction. Ejection fraction measures how much blood the heart pumps with each contraction or beat. Systolic heart ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment ...

About the APEX Phase 2 Clinical Trial for TX45 in Pulmonary Hypertension with HFpEF TX45 is being evaluated in the APEX Phase 2 clinical trial (NCT06616974) in patients with Group 2 Pulmonary ...